ISSUER INFORMATION AND DISCLOSURE STATEMENT PURSUANT
TO
RULE 15c2-11

SECURITIES EXCHANGE ACT OF 1934

PHARMAROTH LABS, INC

DATED: May 21, 2015

CUSIP NUMBER: 71715Y 102

ALL INFORMATION FURNISHED HEREIN HAS BEEN PREPARED FROM THE BOOKS AND RECORDS OF PHARMAROTH LABS, INC. *("COMPANY")* IN ACCORDANCE WITH RULE 15c2-11 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

NO DEALER, SALESMAN OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS NOT CONTAINED HEREIN IN CONNECTION WITH THE COMPANY. ANY REPRESENTATIONS NOT CONTAINED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN MADE OR AUTHORIZED BY THE COMPANY.

DELIVERY OF THIS INFORMATION DOES NOT IMPLY THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE OF THIS ISSUER INFORMATION AND DISCLOSURE STATEMENT.

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Fero Industries, Inc. Name changed to PharmaRoth Labs, Inc. on February 27, 2013

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 8250 W. Charleston Blvd.
Address 2: Suite 110
Address 3: Las Vegas, NV 89117
Phone: 702-544-0195
Email: bhall@pharmaroth.com
Website(s): www.pharmaroth.com

IR Contact
Address 1: 145 Middle St.
Address 2: Ste. 1131
Address 3: Lake Mary FL 32746
Phone: 407-878-5462
Email: mike@parvise.com
Website(s): www.parvise.com

3) Security Information

Trading Symbol: ROTH
Exact title and class of securities outstanding: common stock
CUSIP: 71715Y 102
Par or Stated Value: $.001
Total shares authorized: 500,000,000 as of: 1/1/2007
Total shares outstanding: 317,681,637 as of: 5/21/15

Transfer Agent
Name: Pacific Stock Transfer
Address 1: 4045 S. Spencer St.
Address 2: Suite 403
Address 3: Las Vegas, NV 89119
Phone: 702-361-3033
Is the Transfer Agent registered under the Exchange Act?* Yes: X No: ☐

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

Nature of Offering	Date	Number of Shares	Shareholder	Price*	Value**	Reason for Issue	Trading Status	Notice of Restriction
Section 4(2)	7/1/2012	5,000,000	Boldis		$0.006	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	7/1/2012	5,000,000	Messinger		0.007	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	11/1/2012	4,000,000	McFadden	$ 0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	11/1/2012	2,200,000	Hipsher	0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	11/1/2012	2,000,000	SAS Trust	0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	11/1/2012	18,000,000	Schwartz	0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	12/1/2012	2,000,000	Stefansson	0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	1/1/2013	6,000,000	Hall		0.010	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	1/1/2013	8,000,000	Salti	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	2/1/2013	2,000,000	Lomio	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	3/1/2013	4,000,000	Del Hoyo	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	3/1/2013	2,000,000	Frank	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	5/1/2013	800,000	Doki		0.010	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	5/1/2013	500,000	Soria		0.010	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	5/1/2013	750,000	Jimenez		0.010	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	5/9/2013	3,000,000	Blue Future, Inc.,		0.010	Services, consulting	Restricted	Legend on Cert.
Section 4(2)	6/25/2013	2,000,000	Del Hoyo	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	7/9/2013	13,000,000	Carretara	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	8/14/2013	1,000,000	McCabe	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	9/25/2013	13,000,000	Carretara	0.005		Sale	Restricted	Legend on Cert.
Section 4(2)	12/23/2013	11,914,970	Monohan	0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	12/27/2013	5,000,000	Dziadosz	0.003		Sale	Restricted	Legend on Cert.
Section 4(2)	2/1/2014	4,000,000	McFadden	0.0035		Sale	Restricted	Legend on Cert.
Section 4(2)	2/1/2014	1,500,000	Hipsher	0.0035		Sale	Restricted	Legend on Cert.
Section 4(2)	3/14/2014	11,666,667	Adobe Global LLC	0.0030		Sale	Restricted	Legend on Cert.
Section 4(2)	7/1/2014	500,000	Augusto Nunez	0.011		Services, consulting	Restricted	Legend on Cert.
Section 4(2)	7/1/2014	1,000,000	David Isreal Haro	0.011		Services, consulting	Restricted	Legend on Cert.
Section 4(2)	7/1/2014	1,000,000	Marco Marquez	0.011		Services, consulting	Restricted	Legend on Cert.
Section 4(2)	7/1/2014	2,000,000	John Boldis	0.011		Services, consulting	Restricted	Legend on Cert.
Section 4(2)	7/1/2014	2,500,000	Aetero, Inc	0.011		Services, consulting	Restricted	Legend on Cert.
Section 4(2)	2/17/2015	1,400,000	Hipsher	0.004		Sale	Restricted	Legend on Cert.

*Full price to the company

** For accounting purposes

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otciq.com in the field below.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

FINANCIAL STATEMENTS INCORPORATED BY REFERENCE

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

Development and marketing of proprietary nutraceutical called Sucanon. Sucanon has been show effected in test to effectively treat Type-II Diabetes

B. Date and State (or Jurisdiction) of Incorporation:

December 11, 2000, Colorado

C. the issuer's primary and secondary SIC Codes;

2834 - PHARMACEUTICAL PREPARATIONS

D. the issuer's fiscal year end date;

June 30, 2015

E. principal products or services, and their markets;

Sucanon, a proprietary nutraceutical for the treatment of Type-II Diabetes, sold primarily in Mexico

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The issuer leases two offices. One is in Mexico City and is approximately 1,000 square feet. This is used as an administrative and sales office. The second office is approximately 350 square feet and is located in Las Vegas, NV. This is the Company's headquarters and is the primary location of its books and records.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Officers and Directors
Luis Ornelas Lopez, Chief Executive Officer and Board Member
Barry Hall, CFO

Name of Control Person	Common Stock Beneficially Owned	% of Common Stock
Jonathan Swartz	18,000,000	5.67%

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Frederick M. Lehrer, Esq.
Attorney and Counselor at Law
285 Uptown Blvd., 402
Altamonte Springs, FL 32701
Phone: 321-972-8060
Email: flehrer@securitiesattorney1.com

Accountant or Auditor
Barry Hall
Carlaris LV Inc.
8250 W. Charleston Blvd.
Suite 110
Las Vegas, NV 89117
Phone: 702-544-0195
Email: bh@carlaris.com

Investor Relations Consultant
Name: Mike Irving
Firm: Paramount Advisors, LLC
Address 1: 145 Middle St.
Address 2: Ste. 1131
Address 3: Lake Mary FL 32746
Phone: 407-878-5462
Email: mike@parvise.com

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Luis Ornelas Lopez certify that:

1. I have reviewed this disclosure statement of PharmaRoth Labs, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 12, 2014

/s/ Luis Ornelas Lopez

Luis Ornelas Lopez
CEO

/s/ Barry Hall

Barry Hall
CFO